Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
76%
Type 2 Diabetic Patients
67%
Diabetes
64%
Insulin-like
57%
Growth Factors
50%
Insulin
44%
Non-insulin-dependent Diabetes Mellitus (NIDDM)
42%
Israel
41%
Insulin-like Growth factor-1
39%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
38%
Dipeptidyl peptidase-4 (DPP-4)
37%
Insulin Receptor
32%
Cardiovascular Disease
32%
Impaired Glucose Tolerance
29%
Epidermal Growth Factor
26%
Binding Protein
25%
Glucose-lowering Drugs
25%
Hazard Ratio
25%
Tyrosine Phosphorylation
25%
CVD-REAL
23%
Chronic Kidney Disease
23%
Phosphorylation
23%
Acarbose
23%
Heart Failure
22%
Hypertension
21%
Glucagon-like
20%
Obesity
19%
Insulin Resistance
19%
Hyperinsulinemia
19%
95% Confidence Interval
18%
MDA-MB-231
18%
Insulin Receptor Kinase
18%
Placebo
18%
Metformin
18%
Growth Factor Binding
17%
Breast Cancer Cells
17%
Heart Failure Hospitalization
17%
Cardiovascular Risk Factors
17%
All-cause Mortality
17%
Aurintricarboxylic Acid
17%
Glucose Intolerance
17%
Pre-diabetes (pre-DM)
17%
Tumor Necrosis Factor-α
17%
PDX1
16%
Liver
16%
Protein Synthesis
16%
Israeli
16%
Hemoglobin A1c (HbA1c)
15%
Cardiovascular Events
15%
IGF-binding protein-3
15%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Patient with Type 2 Diabetes
66%
Glucose
61%
Diabetes
54%
Cardiovascular Disease
48%
Insulin
43%
Hypertension
33%
Cardiovascular System
31%
Diabetes Mellitus
28%
Impaired Glucose Tolerance
27%
Glucose Intolerance
25%
Congestive Heart Failure
25%
Health Care Cost
24%
Sodium-Glucose Cotransporter 2 Inhibitors
24%
Breast Cancer
23%
Dipeptidyl Peptidase-4 Inhibitor
23%
Acarbose
21%
Chronic Kidney Disease
20%
Real-World Evidence
19%
Glycon
19%
Hyperinsulinemia
18%
Sitagliptin
17%
Body Mass Index
17%
Hazard Ratio
16%
Prevalence
16%
Placebo
15%
Diseases
15%
Glycemic Control
15%
Real-World Data
14%
Phosphotransferase
13%
Adolescence
13%
Oral Glucose Tolerance Test
13%
Glomerular Filtration Rate
13%
Retrospective Cohort Study
13%
Cardiovascular Risk
13%
Albuminuria
12%
Nephropathy
12%
Glucagon Like Peptide 1
12%
Clinical Trial
12%
Glycemic
11%
Cancer Cell
11%
Differentiated Thyroid Cancer
11%
Adenosine Phosphate
11%
Glucose Homeostasis
11%
Creatinine
11%
Hemoglobin A1c
10%
Hyperglycemia
10%
Insulin Resistance
10%
Risk Reduction
9%
Glycated Hemoglobin
9%
Pharmacology, Toxicology and Pharmaceutical Science
Maturity Onset Diabetes of the Young
95%
Insulin
58%
Glucose
57%
Somatomedin C
49%
sodium glucose cotransporter-2 inhibitors
36%
Dipeptidyl Peptidase IV Inhibitor
34%
Congestive Heart Failure
34%
Rat
30%
Cardiovascular Disease
28%
Aurintricarboxylic Acid
27%
Tyrosine
27%
Diabetes Mellitus
27%
Breast Cancer
26%
Serine
25%
Tumor Necrosis Factor
20%
Binding Protein
19%
Insulin Receptor Substrate 1
19%
Empagliflozin
19%
Insulin Receptor
18%
Insulin Resistance
18%
Impaired Glucose Tolerance
18%
Chronic Kidney Failure
18%
Cycloheximide
16%
Epidermal Growth Factor
16%
Epidermal Growth Factor Receptor
14%
Cohort Study
13%
Cardiovascular Risk
13%
Somatomedin
12%
Prevalence
12%
Glucagon-Like Peptide-1
12%
Sodium Glucose Cotransporter 2 Inhibitor
11%
Threonine
11%
Insulin Receptor Kinase
11%
Lipocortin 1
11%
Follitropin
11%
Somatomedin Binding Protein 2
11%
Cyst Fluid
11%
Semaglutide
11%
Cerebrovascular Accident
10%
Placebo
10%
Receptor
10%
Acarbose
9%
Hemoglobin A1c
9%
Growth Factor
9%
Cotransporter
9%
Protein Tyrosine Kinase
9%
Diseases
9%
Phorbol Ester
8%
Antidiabetic Agent
8%
Clinical Trial
8%
